DEVANI

Design of a vaccine to immunize neonates against GBS infections through a durable maternal immune response

Coordinatore	GLAXOSMITHKLINE VACCINES SRL    more  Organization address address: Via Fiorentina 1 city: SIENA postcode: 53100 contact info Titolo: Dr. Nome: Francesco Cognome: Gulli Email: send email Telefono: -243627 Fax: -244102
Nazionalità Coordinatore	Italy [IT]
Totale costo	5˙923˙577 €
EC contributo	4˙196˙460 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2007-A
Funding Scheme	CP-FP
Anno di inizio	2008
Periodo (anno-mese-giorno)	2008-01-01   -   2011-06-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	GLAXOSMITHKLINE VACCINES SRL  Organization address address: Via Fiorentina 1 city: SIENA postcode: 53100 contact info Titolo: Dr. Nome: Francesco Cognome: Gulli Email: send email Telefono: -243627 Fax: -244102	IT (SIENA)	coordinator	0.00
2	AARHUS UNIVERSITET  Organization address address: Nordre Ringgade 1 city: AARHUS C postcode: 8000 contact info Titolo: Ms. Nome: Lizzie Cognome: Jensen Email: send email Telefono: 4589421642 Fax: 4589421112	DK (AARHUS C)	participant	0.00
3	ALTA RICERCA E SVILUPPO IN BIOTECNOLOGIE SRLU  Organization address address: VIA FIORENTINA 151 city: SIENA postcode: 53100 contact info Titolo: Dr. Nome: Aldo Cognome: Tagliabue Email: send email Telefono: 390577000000 Fax: 390577000000	IT (SIENA)	participant	0.00
4	CENTRE HOSPITALIER UNIVERSITAIRE DE LIEGE  Organization address address: Sart Tilman B35 city: LIEGE postcode: 4000 contact info Titolo: Dr. Nome: Louis Cognome: Pol Email: send email Telefono: 3243667000 Fax: 3243667007	BE (LIEGE)	participant	0.00
5	HEALTH PROTECTION AGENCY HPA  Organization address address: Central Office - 7th Floor, Holborn Gate - High Holborn 330 city: LONDON postcode: WC1V 7PP contact info Titolo: Prof. Nome: Peter S. Cognome: Borriello Email: send email Telefono: 4402080000000 Fax: 4402080000000	UK (LONDON)	participant	0.00
6	ISTITUTO SUPERIORE DI SANITA  Organization address address: Viale Regina Elena 299 city: ROMA postcode: 161 contact info Titolo: Dr. Nome: Rosa Maria Cognome: Martoccia Email: send email Telefono: 390650000000 Fax: 390650000000	IT (ROMA)	participant	0.00
7	NATIONAL CENTER OF INFECTIOUS AND PARASITIC DISEASES  Organization address address: blvd. Yanko Sakazov 26 city: SOFIA postcode: 1504 contact info Titolo: Prof. Nome: Bogdan Cognome: Petrunov Email: send email Telefono: 35929400000000 Fax: 35929433075	BG (SOFIA)	participant	0.00
8	Servicio Andaluz de Salud  Organization address address: AVENIDA DE LA CONSTITUCION 18 city: SEVILLA postcode: 41071 contact info Titolo: Dr. Nome: Arturo D. Cognome: Dominguez Fernandez Email: send email Telefono: 34958020245 Fax: 34958020132	ES (SEVILLA)	participant	0.00
9	STATNI ZDRAVOTNI USTAV  Organization address address: Srobarova 48 city: PRAHA 10 postcode: 10042 contact info Titolo: Dr. Nome: Jaroslav Cognome: Volf Email: send email Telefono: 420267000000 Fax: 420267000000	CZ (PRAHA 10)	participant	0.00
10	UNIVERSITAETSKLINIKUM FREIBURG  Organization address address: HUGSTETTER STRASSE 49 city: FREIBURG postcode: 79106 contact info Nome: Gerhard Cognome: Henninger Email: send email Telefono: +49 761 270 1920 Fax: +49 761 270 1889	DE (FREIBURG)	participant	0.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Direct vaccination cannot prevent diseases that affect neonates in the first days of life. Group B Streptococcus (GBS) is the major cause of neonatal septicemia and meningitis affecting up to one in every thousand live births. Over 80% of cases occur in the first 7 days after birth and the remaining 20% of disease occurs between 8-90 days after birth. Studies carried out in the USA indicate that high titres of maternal antibody to GBS capsular polysaccharides (CPS) correlate with reduced risk of disease in neonates suggesting that maternal immunization may be an effective strategy for delivery of a protective immune response to the child in this early period. The overall objective of this proposal is to design immunization strategies capable of inducing strong durable and placentally transferable protective immune responses against GBS in women in order to fill this gap in early infancy when direct immunization is not possible. Starting with the genome sequence of 8 strains of GBS, Novartis scientists have identified three proteins that confer protection against lethal challenge in neonatal mice from immunized females. Combinations of CPS conjugates plus the recombinant proteins conferred protection against 12 of 12 GBS strains representing the major disease causing serotypes. In order to translate this research into a viable vaccine it will be necessary to identify appropriate adjuvant and delivery systems capable of inducing a protective response which will last through pregnancy. In order to select the serotypes of CPS to include in the vaccine, it will be necessary to understand the serotype distribution of GBS disease in Europe. Furthermore, an immune surrogate of protection will be required to replace efficacy trials. This proposal will address these issues by evaluating adjuvant and delivery in mouse models of disease and by analysis of maternal antibody levels and strain characteristics in cases versus controls obtained from several countries in Europe'

Introduzione (Teaser)

The idea of immunising women to deliver protective antibodies to their babies is gaining ground in the fight against many diseases. The goal of the DEVANI initiative was to utilise this approach for vaccinating against Group B Streptococcus (GBS) to promote protection in newborns.